Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

被引：0
|
作者：
Zandberg, D. [1 ]
Algazi, A. [2 ]
Jimeno, A. [3 ,4 ,5 ]
Good, J. S. [6 ]
Fayette, J. [7 ]
Bouganim, N. [8 ]
Ready, N. [9 ]
Clement, P. M. [10 ]
Goswmi, T. [11 ]
Jarkowski, A. [11 ]
Armstrong, J. M. [11 ]
Asubonteng, K. [11 ]
Melillo, G. [11 ]
Mesia, R. [12 ]
机构：
[1] Univ Maryland, Greenebaum Comprehens Canc Ctr, Hematol Oncol, Baltimore, MD 21201 USA
[2] Univ Calif San Francisco, Oncol, San Francisco, CA 94143 USA
[3] Univ Colorado, Canc Ctr, Dept Med Oncol, Colorado City, CO USA
[4] Univ Colorado, Canc Ctr, Dept Otolaryngol, Colorado City, CO USA
[5] Gates Ctr Regenerat Med, Colorado City, CO USA
[6] Queen Elizabeth Hosp, Inst Head & Neck Studies & Educ, Oncol, Birmingham, W Midlands, England
[7] Univ Lyon, Canc Ctr Ctr Leon Berard, Clin Oncol, Lyon, France
[8] McGill Univ, Hlth Ctr, Dept Oncol, Montreal, PQ, Canada
[9] Duke Univ, Med Ctr, Med Oncol, Durham, NC USA
[10] Univ Hosp Leuven, Dept Oncol, Leuven, Belgium
[11] AstraZeneca, Immunooncol GMD, Gaithersburg, MD USA
[12] Univ Barcelona, Catalan Inst Oncol, Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042O
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study
    Gui, Lin
    Chen, Xinrui
    Xie, Zucheng
    He, Xiaohui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [12] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
    Ho, A. L.
    Adkins, D. R.
    Hanna, G. J.
    Bruce, J.
    Ahn, M. J.
    Docampo, L. Iglesias
    Kang, H.
    Wong, D. J.
    Psyrri, A.
    Gillison, M.
    Brana, I.
    Liu, Y. C.
    Hsieh, C. Y.
    Hong, M. H.
    Zhang, Z.
    Balsara, B.
    Saunders, A.
    Hernandez, A. Gasco
    Dale, S.
    Haddad, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
  • [13] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study
    Chung, Christine
    Bonomi, Marcelo
    Steuer, Conor
    Schell, Michael
    Li, Jiannong
    Johnson, Matthew
    McMullen, Caitlin
    Wadsworth, J. Trad
    Patel, Krupal
    Kish, Julie
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James
    Saba, Nabil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [14] A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Ji, D.
    Sang, Y.
    Liu, X.
    Guo, Y.
    Yang, Y.
    Chen, G.
    Dong, S.
    Wang, Y.
    He, X.
    Ying, H.
    Lu, X.
    Wang, Y.
    Hu, C.
    Ji, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
  • [15] A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530).
    Zandberg, Dan Paul
    Jarkowski, Anthony
    Emeribe, Ugochi A.
    Goswami, Trishna
    Melillo, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [16] A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC
    Colevas, A. Dimitrios Dimitrios
    Dinis, Jose Prime
    Chin, Venessa T.
    Costa, Diogo Alpuim
    Park, John J.
    Fang, Bruno
    Phan, Minh Duc
    Zhang, Yiran
    U'Ren, Lance
    Odegard, Jared
    Curtis, Kelly Kevelin
    Pirtle, Erika
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [17] Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck
    Jimeno, Antonio
    Posner, Marshall R.
    Weiss, Jared
    Wirth, Lori J.
    Saba, Nabil F.
    Cohen, Roger B.
    Popa, Elizabeta C.
    Argiris, Athanassios
    Grossmann, Kenneth F.
    Sukari, Ammar
    Korth, Chris
    Wilson, Dawn
    McClure, Ty
    Alimzhanov, Marat
    Pearsall, Scott
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [18] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [19] Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC)
    Bauman, Julie E.
    Arias-Pulido, Hugo
    Lee, Sang-Joon
    Considine, Michael
    Fekrazad, M. Houman
    Howard, Jason
    Bishop, Justin A.
    Olson, Garth T.
    Jones, Dennie V.
    Fertig, Elana J.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [20] Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Pogorzelski, M.
    Hilser, T.
    Ting, S.
    Vossebein, I
    Gauler, T. C.
    Abendroth, A.
    Lang, S.
    Stuck, B.
    Abu-Jawad, J.
    Stuschke, M.
    Schmid, K. W.
    Schuler, M.
    Kasper, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 307 - 308
12345